ESMO 13th World Congress on Gastrointestinal Cancer

ثبت نشده
چکیده

The ESMO World Congress on Gastrointestinal Cancer took place in Barcelona from the 22nd until the 25th of June and hosted just over 3500 participants and faculty members from around the world, representing nearly 100 countries. The meeting mainly covered malignancies affecting the gastrointestinal tract, focusing on personalized therapy and the multidisciplinary approach. In addition, novel molecular prognostic and predictive tools were discussed. The scientific agenda included 'Meet the Expert' sessions, case discussions, and 24 oral abstract presentations selected from more than 400, which were published in a special supplement of Annals of Oncology. Furthermore, the scientific program presented special nurses' and surgeons' symposia, as well as young medical oncologist and satellite sessions.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

ESMO World Congress on Gastrointestinal Cancer.

This year's annual ESMO World Congress on Gastrointestinal Cancer paid particular attention to the influence of primary tumor sidedness in colorectal cancer as it affects prognosis and treatment outcomes to meet the growing interest in this theory.

متن کامل

ESMO World Congress on Gastrointestinal Cancer And European Post-Chicago Melanoma/Skin Cancer Meeting.

We present sessions on the latest trials and treatments for colorectal cancer from the ESMO World Congress and report on new developments in diagnostics and therapy presented at the European Post-Chicago Melanoma/Skin Cancer Meeting.

متن کامل

Recent Developments in Regorafenib Treatment for Gastrointestinal Cancers: Presentations at the European Society for Medical Oncology (esmo) Congress 2016

The European Society for Medical Oncology (ESMO) Congress was held in Copenhagen, Denmark from 7th–11th October 2016. The use of the promiscuous multikinase inhibitor regorafenib (Stivarga®, BAY 73-4506) in the treatment of cancers of the gastrointestinal (GI) tract was strongly featured at this meeting. Regorafenib targets multiple kinases involved in oncogenesis and angiogenesis, and is US Fo...

متن کامل

State-of-the-art Integration of Multiple Kinase Inhibitors in the Treatment of Gastrointestinal Cancers

Oral multikinase inhibitors have the potential to improve outcomes for patients with a variety of malignancies, such as colorectal cancer, gastric cancer, HCC, and sarcomas, including GISTs. However, many oncologists remain unfamiliar with multikinase inhibitors and their role in treating gastrointestinal tumours, despite >2 years of STATE-OF-THE-ART INTEGRATION OF MULTIPLE KINASE INHIBITORS IN...

متن کامل

Second-line chemotherapy in advanced biliary cancer: a systematic review.

The randomized NCRN phase III ABC-02 trial provided level-A evidence for first-line chemotherapy with cisplatin and gemcitabine combination in advanced biliary cancer (ABC). This systematic literature review aims to evaluate the level of evidence for the use of second-line chemotherapy for patients with ABC in terms of overall survival (OS), response, toxicity and quality of life. Eligible stud...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2013